
    
      The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine
      on silent myocardial ischemia and total ischemic burden in coronary artery disease patients
      with type II diabetes.

      Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive
      on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients
      will repeat the ambulatory ECG monitoring at the end of the study
    
  